b'HADVERTISER GUIDESun PharmaSun Pharma is a wholly owned subsidiary of Sun Pharmaceutical Industries Limited (SPIL). SPIL is the worlds fourth largest specialty generic phar-maceutical company and Indias top pharmaceutical company. A vertically integrated business and a skilled team enables it to deliver high-quality prod-ucts, trusted by customers and patients in over 100 countries across the world, at affordable prices. Its global presence is supported by manufacturing facilities spread across 6 continents and approved by multiple regulatory agencies, cou-pled with a multi-cultural workforce comprising over 50 nationalities. SPIL fosters excellence through innovation supported by strong R&D capabilities across multiple R&D centers, with investments of approximately 6% of annual revenues in R&D. For further information, please visit www.sunpharma.com & follow us on Twitter @SunPharma_Live.Supernus PharmaceuticalsSupernus Pharmaceuticals, Inc. is a specialty pharma-ceutical company focused on developing and commercializing products for the treat-ment of central nervous system (CNS) diseases. Our extensive expertise in product development has been built over the past 30 yearsfueling the success of more than 10 widely recognized products. We are dedicated to the goal of improving the treatment of CNS disorders, including attention-deficit/hyperactivity disorder (ADHD), mood disorders, epilepsy, migraine, and Parkinsons disease.www.supernus.comUCBAt UCB, we come together every day laser-focused on a simple question: How will this create value for people living with severe diseases? We are a global biopharmaceutical company committed to innovation to improve the lives of people with neurological and immunological diseases, finding solutions to meet their unique needs.Please Support Our AdvertisersThe 2022 Directory of Federal Medical Treatment Facilities is provided freeto the readers of U.S. Medicine, at no cost to the federal government or U.S. taxpayer.U.S. Medicine is grateful to these advertisers that make this publication possible.H U.S. MEDICINE 2022 DIRECTORY OF FEDERAL MEDICAL TREATMENT FACILITIESH 209'